CVRx Inc
$ 5.58
1.64%
05 Aug - close price
- Market Cap 145,682,000 USD
- Current Price $ 5.58
- High / Low $ 5.64 / 5.29
- Stock P/E N/A
- Book Value 1.10
- EPS -2.14
- Next Earning Report f
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.27 %
- ROE -1.07 %
- 52 Week High 11.30
- 52 Week Low 4.37
About
CVRx, Inc. develops implantable technology for the treatment of patients with high blood pressure / hypertension and heart failure.
Analyst Target Price
$11.17
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-11 | 2026-02-12 | 2025-11-05 | 2025-08-04 | 2025-05-08 | 2025-02-04 | 2024-10-29 | 2024-07-29 | 2024-04-30 | 2024-01-25 | 2023-10-26 | 2023-07-25 |
| Reported EPS | -0.5 | -0.46 | -0.49 | -0.57 | -0.53 | -0.43 | -0.57 | -0.65 | -1.04 | -0.44 | -0.43 | -0.56 |
| Estimated EPS | -0.5 | -0.44 | -0.5 | -0.52 | -0.57 | -0.38 | -0.47 | -0.55 | -0.54 | -0.55 | -0.58 | -0.58 |
| Surprise | 0 | -0.02 | 0.01 | -0.05 | 0.04 | -0.05 | -0.1 | -0.1 | -0.5 | 0.11 | 0.15 | 0.02 |
| Surprise Percentage | 0% | -4.5455% | 2% | -9.6154% | 7.0175% | -13.1579% | -21.2766% | -18.1818% | -92.5926% | 20% | 25.8621% | 3.4483% |
Next Quarterly Earnings
| Aug 2026 | |
|---|---|
| Reported Date | f |
| Fiscal Date Ending | o |
| Estimated EPS | r |
| Currency | m |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CVRX
2026-07-30 09:40:28
The article details the institutional confidence in CVRx Inc (CVRX), noting its current institutional shareholding score of 5.00, which ranks 107th in the Healthcare Equipment & Supplies industry. Institutional shareholding proportion stands at 65.53%, a decrease of 19.00% quarter-over-quarter. Bill Nygren (OAKMX) is highlighted as the largest institutional shareholder despite an 81.97% decrease in holdings.
2026-07-28 12:45:33
CVRx, Inc., a medical device company focused on neuromodulation solutions for cardiovascular diseases, announced its management team will present at Canaccord Genuity's 46th Annual Growth Conference on August 11, 2026, at 1:00 p.m. ET. The presentation will discuss the company's Barostim technology, the first FDA-approved device using neuromodulation to alleviate heart failure symptoms. A live webcast and archived version will be available on CVRx's investor relations website.
2026-07-28 12:40:33
CVRx (NASDAQ: CVRX), a medical device company specializing in neuromodulation therapies for cardiovascular disease, announced that its management team will present at Canaccord Genuity's 46th Annual Growth Conference in Boston on August 11, 2026, at 1:00 p.m. ET. A live webcast and archived replay of the presentation will be available on the company's investor relations website. The announcement includes historical context detailing past stock reactions to similar conference presentations.
2026-07-28 12:40:33
CVRx, Inc. announced that its management team will present at Canaccord Genuity's 46th Annual Growth Conference in Boston on August 11, 2026, at 1:00 p.m. ET. A live webcast of the presentation will be available on the company's investor relations website, with an archived version accessible for a limited time afterward. CVRx specializes in neuromodulation solutions for cardiovascular diseases, featuring its FDA-approved Barostim™ technology for heart failure patients.
2026-07-28 08:40:33
This article provides a detailed financial overview of CVRx Inc. (CVRX), offering an all-in-one data dashboard for investors. It includes current stock performance, key financial summaries such as income statements, balance sheets, and cash flow statements, and upcoming earnings dates. The report highlights the company's revenue, EPS, net profit, and various financial ratios, along with an analyst rating of "BUY".
2026-07-27 14:39:22
This article details the shareholder structure of CVRx Inc (CVRX), outlining its major shareholders by proportion, including venture capital firms, investment advisors, and corporate entities like Johnson & Johnson Innovation-JJDC, Inc. It also presents institutional shareholding data over several quarters and lists related ETFs that hold CVRX.
